NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.220
+0.160 (5.23%)
At close: May 22, 2026, 4:00 PM EDT
3.202
-0.019 (-0.57%)
After-hours: May 22, 2026, 7:56 PM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, NRx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $40.4. The average 1-year stock price forecast is 1,154.66% higher than the current stock price, while the lowest is $25 (+676.40%) and the highest is $49 (+1,421.74%).
Price Target: $40.4 (+1,154.66%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +955.90% | May 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,297.52% | Apr 27, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $48 → $49 | Strong Buy | Maintains | $48 → $49 | +1,421.74% | Apr 27, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +955.90% | Apr 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +955.90% | Apr 20, 2026 |
Financial Forecast
Revenue This Year
108.48M
from 1.23M
Increased by 8,755.51%
Revenue Next Year
408.32M
from 108.48M
Increased by 276.40%
EPS This Year
0.93
from -1.34
EPS Next Year
2.84
from 0.93
Increased by 205.02%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 253.5M | 582.3M | ||||||
| Avg | 108.5M | 408.3M | ||||||
| Low | 24.5M | 122.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 20,591.4% | 436.8% | ||||||
| Avg | 8,755.5% | 276.4% | ||||||
| Low | 1,900.0% | 12.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.76 | 6.95 | |
| Avg | 0.93 | 2.84 | |
| Low | -0.35 | 0.49 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 646.8% | |
| Avg | - | 205.0% | |
| Low | - | -47.4% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.